The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.

Autor: Herencia-Ropero, Andrea^1,2 (AUTHOR), Llop-Guevara, Alba¹ (AUTHOR) alballop@gmail.com, Staniszewska, Anna D.³ (AUTHOR), Domènech-Vivó, Joanna^4,5 (AUTHOR), García-Galea, Eduardo⁶ (AUTHOR), Moles-Fernández, Alejandro^7,8 (AUTHOR), Pedretti, Flaminia¹ (AUTHOR), Domènech, Heura¹ (AUTHOR), Rodríguez, Olga¹ (AUTHOR), Guzmán, Marta¹ (AUTHOR), Arenas, Enrique J.^9,10,11 (AUTHOR), Verdaguer, Helena^12,13 (AUTHOR), Calero-Nieto, Fernando J.³ (AUTHOR), Talbot, Sara³ (AUTHOR), Tobalina, Luis³ (AUTHOR), Leo, Elisabetta³ (AUTHOR), Lau, Alan³ (AUTHOR), Nuciforo, Paolo¹⁴ (AUTHOR), Dienstmann, Rodrigo⁶ (AUTHOR), Macarulla, Teresa^12,13 (AUTHOR)

Publikováno v: Genome Medicine. 8/26/2024, Vol. 16 Issue 1, p1-17. 17p.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.

Autor: Rhyasen GW; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Hattersley MM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Yao Y; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Dulak A; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Wang W; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Petteruti P; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Dale IL; AstraZeneca, Macclesfield, Cheshire, UK., Boiko S; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Cheung T; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Zhang J; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Wen S; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Castriotta L; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Lawson D; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Collins M; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Bao L; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Ahdesmaki MJ; AstraZeneca, Macclesfield, Cheshire, UK., Walker G; AstraZeneca, Macclesfield, Cheshire, UK., O'Connor G; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Yeh TC; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Rabow AA; AstraZeneca, Macclesfield, Cheshire, UK., Dry JR; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Reimer C; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Lyne P; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Mills GB; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fawell SE; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Waring MJ; AstraZeneca, Macclesfield, Cheshire, UK., Zinda M; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Clark E; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Chen H; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts. raymond.chen@astrazeneca.com.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2016 Nov; Vol. 15 (11), pp. 2563-2574. Date of Electronic Publication: 2016 Aug 29.

Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.

Autor: Goodstal, Samantha M.¹ (AUTHOR) samantha.goodstal@emdserono.com, Lin, Jing¹ (AUTHOR), Crandall, Timothy¹ (AUTHOR), Crowley, Lindsey¹ (AUTHOR), Bender, Andrew T.² (AUTHOR), Pereira, Albertina² (AUTHOR), Soloviev, Maria³ (AUTHOR), Wesolowski, John S.³ (AUTHOR), Iadevaia, Riham¹ (AUTHOR), Schelhorn, Sven-Eric⁴ (AUTHOR), Ross, Edith⁴ (AUTHOR), Morandi, Federica⁵ (AUTHOR), Ma, Jianguo¹ (AUTHOR), Clark, Anderson¹ (AUTHOR)

Publikováno v: Scientific Reports. 11/22/2023, Vol. 13 Issue 1, p1-15. 15p.

补阳还五汤辅助治疗对腰椎间盘突出症术后患者血液流变学、 疼痛介质和生活质量的影响.

Autor: 孟兰萱¹ a12qwer09@163.com, 周 峻¹, 唐向盛², 杨 峰², 麻昊宁², 谭明生² zrtanms@sina.com

Publikováno v: Progress in Modern Biomedicine. 2022, Vol. 22 Issue 16, p3041-3045. 5p.

PRC2-EZH1 contributes to circadian gene expression by orchestrating chromatin states and RNA polymerase II complex stability.

Autor: Liu P; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia. peng.liu@kaust.edu.sa., Nadeef S; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Serag MF; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, Bioscience Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Paytuví-Gallart A; Sequentia Biotech SL, Carrer Comte D'Urgell 240, Barcelona, 08036, Spain., Abadi M; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, Bioscience Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Della Valle F; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia.; Altos Labs, Institute of Science, San Diego, CA, 92121, USA., Radío S; Sequentia Biotech SL, Carrer Comte D'Urgell 240, Barcelona, 08036, Spain., Roda X; Sequentia Biotech SL, Carrer Comte D'Urgell 240, Barcelona, 08036, Spain., Dilmé Capó J; Sequentia Biotech SL, Carrer Comte D'Urgell 240, Barcelona, 08036, Spain., Adroub S; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Hosny El Said N; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Fallatah B; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Celii M; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Messa GM; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Wang M; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, Bioscience Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Li M; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, Bioscience Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Tognini P; University of California, Irvine, Department of Biological Chemistry, School of Medicine, Center for Epigenetics and Metabolism, Irvine, CA, 92697, USA.; Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, 56126, Italy., Aguilar-Arnal L; University of California, Irvine, Department of Biological Chemistry, School of Medicine, Center for Epigenetics and Metabolism, Irvine, CA, 92697, USA.; Universidad Nacional Autónoma de México, Instituto de Investigaciones Biomédicas, Mexico City, 04510, Mexico., Habuchi S; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, Bioscience Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia., Masri S; University of California Irvine, Department of Biological Chemistry, Chao Family Comprehensive Cancer Center, Irvine, CA, 92697, USA., Sassone-Corsi P; University of California, Irvine, Department of Biological Chemistry, School of Medicine, Center for Epigenetics and Metabolism, Irvine, CA, 92697, USA., Orlando V; King Abdullah University of Science and Technology, KAUST, Biological and Environmental Sciences and Engineering Division, KAUST Environmental Epigenetics Program, Thuwal, 23955-6900, Kingdom of Saudi Arabia. valerio.orlando@kaust.edu.sa.

Publikováno v: The EMBO journal [EMBO J] 2024 Oct 21. Date of Electronic Publication: 2024 Oct 21.